Latest On Intec Pharma Ltd (NTEC):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-07-26 20:07 EST | News | Intec Pharma sinks on reverse share split | N/A |  |
| 2021-03-18 05:24 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-17 13:20 EST | Earnings Estimate | An EPS average of -$1.55 is estimated for the 2022 year. | Sell | |
| 2021-03-17 13:20 EST | Earnings Estimate | An EPS average of -$0.86 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-03-17 05:01 EST | News | Intec Pharma (NTEC) shares rocket 87% on merger deal with Decoy Biosystems | N/A | |
About Intec Pharma Ltd (NTEC):
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a read more...Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program; and a feasibility agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.
General
- Name Intec Pharma Ltd
- Symbol NTEC
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:20
- Last Split Date2020-10-30
- Fiscal Year EndDecember
- IPO Date2015-08-04
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.intecpharma.com
Valuation
- Price/Book (Most Recent Quarter) 1.05
- Enterprise Value EBITDA 0.03
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.71
- Next Year EPS Estimate -$1.55
- Next Quarter EPS Estimate -$0.99
- Return on Assets -41%
- Return on Equity -108%
- Earnings Per Share -$1.28
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 22.15 million
- EBITDA -41806000
- Analyst Target Price $9
- Book Value Per Share $4.58
Share Statistics
- Shares Outstanding 3.95 million
- Shares Float 3.82 million
- % Held by Insiders 874%
- % Held by Institutions 21.82%
- Shares Short 545490
- Shares Short Prior Month 517065
- Short Ratio 0.47
- Short % of Float 14%
- Short % of Shares Outstanding 14%
Technicals
- Beta 1.21
- 52 Week High $11.2
- 52 Week Low $2.2
- 50 Day Moving Average 5.02
- 200 Day Moving Average 4.45
Dividends
- Dividend Date 2020-10-30
- ExDividend Date N/A
- Dividend Yield 0%
Intec Pharma Ltd (NTEC) Dividend Calendar:
NTEC's last dividend payment was made to shareholders on October 30, 2020.
Intec Pharma Ltd (NTEC) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Intec Pharma Ltd (NTEC) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Intec Pharma Ltd (NTEC) Chart:
Intec Pharma Ltd (NTEC) News:
Below you will find a list of latest news for Intec Pharma Ltd (NTEC) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Intec Pharma Ltd (NTEC) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Intec Pharma Ltd (NTEC) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-04 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-29 | 8-K (Current report) | |
| 2020-10-08 | 8-K (Current report) | |
| 2020-10-02 | 8-K (Current report) | |
| 2020-09-18 | 8-K (Current report) | |
| 2020-09-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-08-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-17 | 8-K (Current report) | |
| 2020-07-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-17 | 4 (Statement of changes in beneficial ownership of securities) | |
Intec Pharma Ltd (NTEC) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Intec Pharma Ltd (NTEC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 874%
Institutional Ownership: 2182%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-02-04 | Pharma Technologies Ltd. Dexcel | 10% Share Holder | Sell | 110,000.00 | 0.29 | 31,900.00 | 4,234,897.00 | |
| 2020-02-03 | Pharma Technologies Ltd. Dexcel | 10% Share Holder | Sell | 80,000.00 | 0.32 | 25,440.00 | 4,344,897.00 | |
| 2020-01-31 | Pharma Technologies Ltd. Dexcel | 10% Share Holder | Sell | 725,951.00 | 0.31 | 224,318.86 | 4,424,897.00 | |
| 2019-11-19 | Issac Silberman | Director | Sell | 1,000.00 | 0.50 | 504.00 | 4,000.00 | |
| 2019-08-28 | Jeffrey A Meckler | Chief Executive Officer | Buy | 20,000.00 | 0.68 | 13,620.00 | 196,761.00 | |
| 2019-08-27 | ANTHONY J MADDALUNA | Director | Buy | 25,000.00 | 0.47 | 11,750.00 | 53,570.00 | |
| 2019-08-23 | JOHN W KOZARICH | Director | Buy | 100,000.00 | 0.46 | 45,900.00 | 151,761.00 | |
| 2019-08-23 | Jeffrey A Meckler | Chief Executive Officer | Buy | 100,000.00 | 0.46 | 45,700.00 | 176,761.00 | |